Abstract:A prospective and retrospective study had been carried out between January 2013 to December 2015 for evaluation of the overall survival (OS) & disease free survival (DFS) rate of HER2 positive breast cancer patients with Trastuzumab combined with cytotoxic chemotherapy and patients who only takes chemotherapy alone. A randomized control trial was run with the 130 patients having HER2 positive breast cancer in the Rajshahi Medical College and Hospital and different private hospitals and Clinics of Rajshahi … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.